Clinical trials: Androgens
Osteoporosis, Prostate Cancer
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more…
- Trial name
- NCT00003903
- Testing
- management of therapy complications
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Rochester
Osteoporosis, Prostate Cancer
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
RATIONALE: Preventing bone loss in patients who are undergoing androgen ablation for prostate cancer may decrease the risk of fractures and may help patients live more comfortably.
- Trial name
- NCT00043069
- Testing
- calcium carbonate, cholecalciferol, Estrogen Antagonists
- Where
- 114 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00060437
- Testing
- perifosine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that…
- Trial name
- NCT00038194
- Testing
- imatinib mesylate, docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
- Trial name
- NCT02796898
- Testing
- SM88 (Cohort 1), SM88 (Cohort 2)
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tyme, Inc
Prostate Cancer
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- DASL-HiCaP (NCT04136353)
- Testing
- Darolutamide, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Where
- 93 sites in United States, Australia and 4 more
- Volunteers
- 1,100 people
- Sponsor
- University of Sydney
Prostate Cancer, Prostatic Neoplasms
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer.
- Trial name
- NCT00878436
- Testing
- Panobinostat, Bicalutamide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.
- Trial name
- ZENITH (NCT00686036)
- Testing
- vandetanib
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer
Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic…
- Trial name
- NCT00003238
- Testing
- perillyl alcohol
- Where
- 8 sites in United States
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
- Trial name
- GAINPCCONTROL (NCT06908694)
- Testing
- Semaglutide Pen Injector
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer
The purpose of this study is to evaluate the incidence of urinary and rectal acute side effects of a pelvic and prostatic intensity-modulated arctherapy with simultaneous integrated boost (SIB-IMRT)combined with long-term…
- Trial name
- NCT01704027
- Testing
- Simultaneous integrated boost intensity-modulated arctherapy, Androgen deprivation
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Georges Francois Leclerc
Prostate Cancer, Cardiovascular Death
Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not this…
- Trial name
- NCT00651222
- Testing
- No intervention was required
- Where
- United States
- Sponsor
- Prostate Cancer Foundation of Chicago
Cachexia
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
GSK2881078 is a selective androgen receptor modulator (SARM) that is being evaluated for effects on muscle growth and strength in subjects with muscle wasting to improve their physical function.
- Trial name
- NCT02567773
- Testing
- GSK2881078, Itraconazole
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Salivary Gland Carcinoma
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not…
- Trial name
- NCT03942653
- Testing
- Goserelin Acetate, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Manish Patel
Prostate Cancer
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
- Trial name
- NCT00134654
- Testing
- Premarin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
- Trial name
- NCT00245466
- Testing
- Degarelix
- Volunteers
- 88 people
- Sponsor
- Ferring Pharmaceuticals
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Prostate Cancer
FIRMAGON® Intensive Drug Monitoring
To evaluate the safety profile of FIRMAGON® (to fulfill the regulatory authority's requirement of Intensive Drug Monitoring in Chinese participants with prostate cancer need androgen deprivation therapy [ADT] treated with…
- Trial name
- NCT05181800
- Testing
- Degarelix Cohort
- Where
- China
- Volunteers
- 1,454 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms, Exercise
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC). The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased…
- Conditions
- Prostatic Neoplasms, Exercise, Soccer Training, Androgen Deprivation Therapy
- Trial name
- NCT01711892
- Testing
- Soccer training
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Copenhagen
Infertility, Female, Ovarian Reserve
hCG Priming in Women With Diminished Ovarian Reserve
The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro…
- Conditions
- Infertility, Female, Ovarian Reserve, In Vitro Fertilization (IVF)
- Trial name
- NCT07108621
- Testing
- Choriongonadotropin alfa (hCG)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Kristine Loessl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.